Shitara K - Search Results

1

The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer.

Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, Arita T, Hirata T, Goto H, Wada N, Kobayashi M, Shibutani T, Okabayashi T, Nakamaru K, Kawazoe A, Togashi Y, Nishikawa H, Shitara K. Koganemaru S, et al. Among authors: shitara k. Cancer Res Commun. 2024 Dec 16. doi: 10.1158/2767-9764.CRC-24-0302. Online ahead of print. Cancer Res Commun. 2024. PMID: 39679910 Free article.

2

[Cytotoxic Agents and Immune Checkpoint Inhibitors].

Kawazoe A, Shitara K. Kawazoe A, et al. Among authors: shitara k. Gan To Kagaku Ryoho. 2017 Sep;44(9):717-721. Gan To Kagaku Ryoho. 2017. PMID: 28912395 Japanese.

3

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8⁺ T cells in the tumor microenvironment.

Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H, Shitara K. Tada Y, et al. Among authors: shitara k. J Immunother Cancer. 2018 Oct 11;6(1):106. doi: 10.1186/s40425-018-0403-1. J Immunother Cancer. 2018. PMID: 30314524 Free PMC article. Clinical Trial.

4

Dawn of precision medicine on gastric cancer.

Ishii T, Kawazoe A, Shitara K. Ishii T, et al. Among authors: shitara k. Int J Clin Oncol. 2019 Jul;24(7):779-788. doi: 10.1007/s10147-019-01441-x. Epub 2019 Apr 11. Int J Clin Oncol. 2019. PMID: 30976939 Review.

5

Next-generation sequencing and biomarkers for gastric cancer: what is the future?

Kawazoe A, Shitara K. Kawazoe A, et al. Among authors: shitara k. Ther Adv Med Oncol. 2019 Jun 21;11:1758835919848189. doi: 10.1177/1758835919848189. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31258627 Free PMC article. Review.

6

Trifluridine/tipiracil for the treatment of metastatic gastric cancer.

Kawazoe A, Shitara K. Kawazoe A, et al. Among authors: shitara k. Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):65-70. doi: 10.1080/17474124.2020.1715209. Epub 2020 Jan 14. Expert Rev Gastroenterol Hepatol. 2020. PMID: 31920125 Review.

7

Antibody-drug conjugates to treat gastric cancer.

Koganemaru S, Shitara K. Koganemaru S, et al. Among authors: shitara k. Expert Opin Biol Ther. 2021 Jul;21(7):923-930. doi: 10.1080/14712598.2020.1802423. Epub 2020 Aug 13. Expert Opin Biol Ther. 2021. PMID: 32713216 Review.

8

Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine.

Mishima S, Kawazoe A, Shitara K. Mishima S, et al. Among authors: shitara k. Expert Opin Drug Saf. 2020 Sep;19(9):1063-1068. doi: 10.1080/14740338.2020.1805428. Epub 2020 Aug 12. Expert Opin Drug Saf. 2020. PMID: 32741230 Review.

9

The New Era of Immunotherapy in Gastric Cancer.

Takei S, Kawazoe A, Shitara K. Takei S, et al. Among authors: shitara k. Cancers (Basel). 2022 Feb 18;14(4):1054. doi: 10.3390/cancers14041054. Cancers (Basel). 2022. PMID: 35205802 Free PMC article. Review.

10

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience.

Kubota Y, Aoki Y, Kawazoe A, Shitara K. Kubota Y, et al. Among authors: shitara k. Cancer Manag Res. 2022 Oct 21;14:3083-3094. doi: 10.2147/CMAR.S351791. eCollection 2022. Cancer Manag Res. 2022. PMID: 36275782 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

464 results

Search Page

Filters